Physician profile
Tabitha Salzer
NPI 1699319939
$19,748.71
in general payments reported to CMS, 2019-2025
23 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,233 · 2022: $2,494 · 2023: $2,225 · 2024: $3,080 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,446 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,400 · Consulting Fee: $740 · Travel and Lodging: $301 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,445.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,400.00 |
| Consulting Fee | $740.00 |
| Travel and Lodging | $301.03 |
| Education | $134.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,354.91 | 2021-2025 | |
| Alkermes, INC. | $1,953.87 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $1,616.18 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $1,437.19 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,381.65 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,137.50 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $766.21 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Otsuka America Pharmaceutical, INC. | $646.70 | 2022-2025 | Nuedexta, Abilify Mycite, Rexulti |
| Axsome Therapeutics, INC. | $579.84 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $447.09 | 2021-2025 | Trintellix |
| Indivior INC. | $321.49 | 2021-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $258.20 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $177.51 | 2022 | |
| Bausch Health US, LLC | $146.79 | 2023-2025 | Aplenzin |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $103.15 | 2022 | |
| Lundbeck LLC | $79.89 | 2023-2025 | Rexulti |
| Corium, LLC | $74.56 | 2023-2025 | Azstarys, Azstarys |
| Jazz Pharmaceuticals INC. | $36.20 | 2021 | |
| Almatica Pharma LLC | $35.68 | 2022-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $31.61 | 2023 | Quviviq |
| Lilly USA, LLC | $20.64 | 2025 | Kisunla |
| Supernus Pharmaceuticals, INC. | $16.85 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Salzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.